Literature DB >> 24771513

Cortical interneuron loss and symptom heterogeneity in Huntington disease.

Eric H Kim1, Doris C V Thu, Lynette J Tippett, Dorothy E Oorschot, Virginia M Hogg, Richard Roxburgh, Beth J Synek, Henry J Waldvogel, Richard L M Faull.   

Abstract

OBJECTIVE: The cellular basis of variable symptoms in Huntington disease (HD) is unclear. One important possibility is that degeneration of the interneurons in the cerebral cortex, which play a critical role in modulating cortical output to the basal ganglia, might play a significant role in the development of variable symptomatology in HD. This study aimed to examine whether symptom variability in HD is specifically associated with variable degeneration of cortical interneurons.
METHODS: We undertook a double-blind study using stereological cell counting methods to quantify the 3 major types of γ-aminobutyric acidergic interneurons (calbindin-D28k, calretinin, parvalbumin) in 13 HD cases of variable motor/mood symptomatology and 15 matched control cases in the primary motor and anterior cingulate cortices.
RESULTS: In the primary motor cortex, there was a significant loss (57% reduction) of only calbindin interneurons (p=0.022) in HD cases dominated by motor symptoms, but no significant interneuron loss in cases with a dominant mood phenotype. In contrast, the anterior cingulate cortex showed a major significant loss in all 3 interneuron populations, with 71% loss of calbindin (p=0.001), 60% loss of calretinin (p=0.001), and 80% loss of parvalbumin interneurons (p=0.005) in HD cases with major mood disorder, and no interneuron loss was observed in cases with major motor dysfunction.
INTERPRETATION: These findings suggest that region-specific degeneration of cortical interneurons is a key component in understanding the neural basis of symptom heterogeneity in HD.
© 2014 American Neurological Association.

Entities:  

Mesh:

Year:  2014        PMID: 24771513     DOI: 10.1002/ana.24162

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.

Authors:  Mark F Mehler; Jenna R Petronglo; Eduardo E Arteaga-Bracho; Maria E Gulinello; Michael L Winchester; Nandini Pichamoorthy; Stephen K Young; Christopher D DeJesus; Hifza Ishtiaq; Solen Gokhan; Aldrin E Molero
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

3.  Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Authors:  Sandra M Holley; Laurie Galvan; Talia Kamdjou; Carlos Cepeda; Michael S Levine
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

Review 4.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

5.  Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.

Authors:  Ana María Estrada-Sánchez; Courtney L Blake; Scott J Barton; Andrew G Howe; George V Rebec
Journal:  J Neurophysiol       Date:  2019-11-06       Impact factor: 2.714

6.  Pathoarchitectonics of the cerebral cortex in chorea-acanthocytosis and Huntington's disease.

Authors:  J Liu; H Heinsen; L T Grinberg; E Alho; E Amaro; C A Pasqualucci; U Rüb; K Seidel; W den Dunnen; T Arzberger; C Schmitz; M C Kiessling; B Bader; A Danek
Journal:  Neuropathol Appl Neurobiol       Date:  2018-06-10       Impact factor: 8.090

7.  Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Courtney L Burroughs; Stephen Cavaliere; Scott J Barton; Shirley Chen; X William Yang; George V Rebec
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

8.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

9.  Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease.

Authors:  Aldrin E Molero; Eduardo E Arteaga-Bracho; Christopher H Chen; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Solen Gokhan; Kamran Khodakhah; Mark F Mehler
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

10.  Induction of specific neuron types by overexpression of single transcription factors.

Authors:  Yusuke Teratani-Ota; Kohei Yamamizu; Yulan Piao; Lioudmila Sharova; Misa Amano; Hong Yu; David Schlessinger; Minoru S H Ko; Alexei A Sharov
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-06-01       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.